Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.69 |
| ▸ | GLP1R | P43220 | 12/20 | 0.68 |
| ▸ | CALCA | P06881 | 2/20 | 0.66 |
| ▸ | NPY1R | P25929 | 1/20 | 0.65 |
| ▸ | NPY2R | P49146 | 1/20 | 0.65 |
| ▸ | NPY4R | P50391 | 1/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.65 |
| ▸ | GIPR | P48546 | 7/20 | 0.64 |
| ▸ | GCGR | P47871 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cecropin A SCHEMBL29361111 | 0.98 | KEAP1 (0.67) | KEAP1GLP1RCALCANPY1RNPY2R | |
| Cecropin Ad SCHEMBL29842479 | 0.95 | NPY1R (0.68) | KEAP1GLP1RCALCANPY1RNPY2R | |
| Cecropin B SCHEMBL29355118 | 0.93 | KEAP1 (0.69) | KEAP1GLP1RGCGR | |
| SCHEMBL29949636 | 0.91 | NPY1R (0.71) | KEAP1GLP1RCALCANPY1RNPY2R | |
| SCHEMBL29922501 | 0.91 | GLP1R (0.76) | KEAP1GLP1RGIPRGCGR | |
| SCHEMBL29922531 | 0.90 | GLP1R (0.76) | KEAP1GLP1RGIPRGCGR | |
| SCHEMBL30495604 | 0.90 | GLP1R (0.71) | KEAP1GLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL31182815 | 0.90 | NPY2R (0.73) | KEAP1GLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL29444962 | 0.90 | KEAP1 (0.69) | KEAP1GLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL29391164 | 0.90 | GLP1R (0.65) | KEAP1GLP1RCALCANPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115487114-B | Antibacterial peptide composition, acne-removing cream containing antibacterial peptide composition and preparation method of acne-removing cream | 广东粤港澳大湾区黄埔材料研究院 | 2023-10-03 | — | — | CN | claimed |
| US-RE50618-E1 | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same | PHARMAIN CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| CN-116785447-B | Novel conjugates of montelukast and peptides | 艾缇亚(上海)制药有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-117487750-B | Use of NK cells in the treatment of immune related disorders | 青岛西凯生物技术有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117487750-A | Use of NK cells in the treatment of immune related disorders | 青岛西凯生物技术有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-115487114-B | Antibacterial peptide composition, acne-removing cream containing antibacterial peptide composition and preparation method of acne-removing cream | 广东粤港澳大湾区黄埔材料研究院 | 2023-10-03 | — | — | CN | disclosed |
| EP-3317294-B1 | STABILIZED ANTI-MICROBIAL PEPTIDES | DANA FARBER CANCER INST INC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3519426-B1 | ANTIMICROBIAL PEPTIDES COMPRISING EPSILON LYSINE RESIDUES | SINGAPORE HEALTH SERV PTE LTD (SG) | 2023-02-15 | — | — | EP | disclosed |
| CN-115487114-A | Antibacterial peptide composition, acne-removing cream containing antibacterial peptide composition and preparation method of acne-removing cream | 广东粤港澳大湾区黄埔材料研究院 | 2022-12-20 | — | — | CN | disclosed |
| US-11396531-B2 | Antimicrobial peptides comprising epsilon lysine residues | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2022-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396531-B2 | Antimicrobial peptides comprising epsilon lysine residues | ARG1, MYADM, ARG2 | KEAP1 4194/4885GLP1R 452/4885CALCA 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.